[ad_1]
Article content material
Enabling native oncology genomic testing to broaden affected person entry to expedited, customized care the place it issues most – near residence
ST. LOUIS — PierianDx, the worldwide chief in medical genomics information, at this time introduced that it’ll associate with Florida Most cancers Specialists & Analysis Institute (FCS) to assist expanded entry to the very best high quality genomic testing on stable tumors and hematologic malignancies and lymph nodes leveraging NGS expertise. Underneath the partnership, FCS will regionally analyze and interpret sequencing information generated with the Illumina TruSight™ Oncology 500 Analysis Use Solely assay and the Invitae VariantPlex®, LiquidPlex™, and FusionPlex® panels utilizing PierianDx Medical Genomic Workspace™ (CGW) to quickly and precisely detect mutations and supply the perfect therapeutic choices for sufferers.
Article content material
Historic approaches to precision medication testing embody centralized testing carried out at massive nationwide laboratories the place the laboratory usually has little-to-no interplay with the affected person and restricted treating doctor interplay. By localizing genomic testing, FCS sufferers will profit from extra direct entry to testing throughout the context of care. Providing these assessments within the FCS laboratory may even allow improved collaboration between the diagnostic staff who interpret the check outcomes and the treating physicians, which drives alignment throughout the care staff and will increase confidence within the medical utility of genomic testing.
The genomic check outcomes at Florida Most cancers Specialists might be delivered through a customizable report generated by the PierianDx CGW. Powered by a complete knowledgebase and safe and scalable information evaluation platform, the PierianDx CGW will allow Florida Most cancers Specialists to shortly and precisely classify and interpret variants to tell remedy or match sufferers to the precise trial throughout the observe’s massive community of collaborating medical trials.
In accordance with Florida Most cancers Specialists CEO Nathan H. Walcker, “We see super medical and strategic worth to performing this essential testing in-house. By providing in-house genomic testing, we’ll proceed to hunt the perfect choices for look after our affected person inhabitants by shortly and effectively offering current therapies in addition to optimizing medical trial matching alternatives. We look ahead to partnering with PierianDx to supply even larger instruments to our doctor companions at FCS and enabling wider entry to excessive complexity testing to the sufferers we’re privileged to serve.”
“We’re thrilled to supply our best-in-class bioinformatics and information platform to assist customized, community-based most cancers care,” states Mark McDonough, CEO of PierianDx. “Partnering with modern establishments like Florida Most cancers Specialists aligns completely with our mission to democratize medical genomics and to optimally serve physicians and the sufferers they deal with.”
About PierianDx
Based in 2014, PierianDx is targeted on advancing most cancers diagnostics and making focused therapeutics extra accessible to healthcare techniques, laboratories, and sufferers worldwide. Its industry-leading medical genomics applied sciences, IVD-ready knowledgebase and reporting resolution, and experience ship essentially the most built-in, trusted, and collaborative method throughout the medical care spectrum. From genomic sequencing and biomedical informatics within the laboratory to reporting and choice assist on the affected person’s bedside, PierianDx drives the adoption of genomics in medical care and accelerates the combat towards somatic most cancers and hereditary ailments. For extra info go to www.pieriandx.com.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20211007005344/en/
Contacts
Lisa Owen
lowen@pieriandx.com
#distro
[ad_2]
Source